Targeting the OXE receptor as a potential novel therapy for asthma

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• 5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a key metabolite involved in eosinophil chemoattraction.
• The OXE receptor (encoded by OXER1) mediates 5-oxo-ETE's effects and is expressed on various immune cells.
• Eosinophil infiltration induced by 5-oxo-ETE suggests a role in eosinophilic diseases.

Purpose of the Study:

• To synthesize selective OXE receptor antagonists.
• To investigate the pathophysiological role of 5-oxo-ETE in eosinophilic diseases.
• To identify potential novel therapeutics for asthma and related conditions.

Main Methods:

• Synthesis of indole-based compounds as OXE receptor antagonists.
• Evaluation of compound potency, including inhibition of 5-oxo-ETE-induced calcium mobilization.
• Assessment of antagonist efficacy in animal models of allergic inflammation.

Main Results:

• S-Y048 identified as a potent OXE receptor antagonist with high affinity (IC50 = 20 pM).
• S-Y048 demonstrated a long half-life after oral administration.
• S-Y048 successfully inhibited eosinophil infiltration and pulmonary inflammation in primate models.

Conclusions:

• This study provides the first evidence for 5-oxo-ETE's pathophysiological role in mammals.
• Potent and selective OXE receptor antagonists like S-Y048 represent promising therapeutic agents.
• Targeting the OXE receptor may be a viable strategy for treating eosinophilic diseases.